Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aurelius Health Group vs Basal Health

Aurelius Health Group
Graded #275

Higher grade

vs+14.599999999999994
Basal Health
Graded #494

Lower grade

The verdict

Aurelius Health Group takes it — 62.3/100 to 47.7/100.

Aurelius Health Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aurelius Health Group is a telehealth platform built around compounded tirzepatide microdosing — a low-dose dual GIP/GLP-1 protocol rather than standard full-dose therapy — with optional NAD+, L-carnitine,…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAurelius Health Group +15
60
45
Dose & formulationAurelius Health Group +12
52
40
Clinical oversightAurelius Health Group +28
76
48
Labs & monitoringAurelius Health Group +13
63
50
FulfillmentAurelius Health Group +3
61
58
Contract termsAurelius Health Group +6
61
55
Aurelius Health Group · left barBasal Health · right bar

The numbers

MetricAurelius Health GroupBasal Health
WeighScore62.3/10047.7/100
GradeCC
Scorecard rank#275#494
SemaglutideNot disclosedNot disclosed
Tirzepatide$199/mo (microdose tier, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Aurelius Health Group

Graded #275 · C

Strengths

  • Pricing fully published and bundled: $89 first month, then $199/mo all-in — more transparent than most compounded brands
  • LegitScript Certified
  • Care-inclusive model: consults, monthly monitoring, and secure messaging rather than Rx-only
  • Unusually candid about the limited evidence base for microdosing

Where it loses points

  • Microdose-only model — sub-therapeutic doses have thinner trial evidence and likely smaller weight loss than full-dose tirzepatide
  • No semaglutide or standard full-dose option
  • No named compounding pharmacy partner
  • No state list and no named medical director or pharmacist-in-charge
Basal Health

Graded #494 · C

Strengths

  • Stated nationwide coverage (50 states + DC)
  • Metabolic-framework positioning rather than single-product
  • Clinician-supervised dosing rather than a fixed protocol
  • Adaptive monitoring approach

Where it loses points

  • No pricing shown publicly — you must complete intake to see cost
  • Compounding pharmacy partner not named
  • GLP-1 molecules not specified (semaglutide vs tirzepatide vs oral)
  • No LegitScript badge visible on the homepage
  • No FDA compounded-medication disclaimer on the pages reviewed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard